Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction
Neuroinflammation is involved in the onset or progression of various neurodegenerative diseases. Initiation of neuroinflammation is triggered by endogenous substances (damage-associated molecular patterns) and/or exogenous pathogens. Activation of glial cells (microglia and astrocytes) is widely recognized as a hallmark of neuroinflammation and triggers the release of proinflammatory cytokines, leading to neurotoxicity and neuronal dysfunction. Another feature associated with neuroinflammatory diseases is impairment of the blood-brain barrier (BBB). The BBB, which is composed of brain endothelial cells connected by tight junctions, maintains brain homeostasis and protects neurons. Impairment of this barrier allows trafficking of immune cells or plasma proteins into the brain parenchyma and subsequent inflammatory processes in the brain. Besides neurons, activated glial cells also affect BBB integrity. Therefore, BBB dysfunction can amplify neuroinflammation and act as a key process in the development of neuroinflammation. BBB integrity is determined by the integration of multiple signaling pathways within brain endothelial cells through intercellular communication between brain endothelial cells and brain perivascular cells (pericytes, astrocytes, microglia, and oligodendrocytes). For prevention of BBB disruption, both cellular components, such as signaling molecules in brain endothelial cells, and non-cellular components, such as inflammatory mediators released by perivascular cells, should be considered. Thus, understanding of intracellular signaling pathways that disrupt the BBB can provide novel treatments for neurological diseases associated with neuroinflammation. In this review, we discuss current knowledge regarding the underlying mechanisms involved in BBB impairment by inflammatory mediators released by perivascular cells.
Top-30
Journals
|
5
10
15
20
25
30
35
|
|
|
International Journal of Molecular Sciences
34 publications, 7.83%
|
|
|
Cells
11 publications, 2.53%
|
|
|
Molecular Neurobiology
8 publications, 1.84%
|
|
|
Frontiers in Cellular Neuroscience
7 publications, 1.61%
|
|
|
International Immunopharmacology
7 publications, 1.61%
|
|
|
Frontiers in Immunology
6 publications, 1.38%
|
|
|
Frontiers in Pharmacology
6 publications, 1.38%
|
|
|
Brain Sciences
6 publications, 1.38%
|
|
|
Scientific Reports
6 publications, 1.38%
|
|
|
Frontiers in Aging Neuroscience
5 publications, 1.15%
|
|
|
Journal of Neuroinflammation
5 publications, 1.15%
|
|
|
CNS Neuroscience and Therapeutics
5 publications, 1.15%
|
|
|
Brain Behavior & Immunity - Health
4 publications, 0.92%
|
|
|
Experimental Neurology
4 publications, 0.92%
|
|
|
Journal of Cerebral Blood Flow and Metabolism
4 publications, 0.92%
|
|
|
Neuroscience
4 publications, 0.92%
|
|
|
Journal of Clinical Medicine
4 publications, 0.92%
|
|
|
Fluids and Barriers of the CNS
3 publications, 0.69%
|
|
|
Neurology
3 publications, 0.69%
|
|
|
Frontiers in Neurology
3 publications, 0.69%
|
|
|
Frontiers in Psychiatry
3 publications, 0.69%
|
|
|
Frontiers in Neuroscience
3 publications, 0.69%
|
|
|
Neuroscience Letters
3 publications, 0.69%
|
|
|
bioRxiv
3 publications, 0.69%
|
|
|
Behavioural Brain Research
3 publications, 0.69%
|
|
|
Neural Regeneration Research
3 publications, 0.69%
|
|
|
Brain Research Bulletin
3 publications, 0.69%
|
|
|
Communications Biology
3 publications, 0.69%
|
|
|
Journal of Ethnopharmacology
3 publications, 0.69%
|
|
|
5
10
15
20
25
30
35
|
Publishers
|
20
40
60
80
100
120
|
|
|
Elsevier
115 publications, 26.5%
|
|
|
MDPI
79 publications, 18.2%
|
|
|
Springer Nature
74 publications, 17.05%
|
|
|
Frontiers Media S.A.
43 publications, 9.91%
|
|
|
Wiley
27 publications, 6.22%
|
|
|
Cold Spring Harbor Laboratory
12 publications, 2.76%
|
|
|
SAGE
11 publications, 2.53%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
10 publications, 2.3%
|
|
|
Taylor & Francis
9 publications, 2.07%
|
|
|
American Chemical Society (ACS)
5 publications, 1.15%
|
|
|
IMR Press
4 publications, 0.92%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 0.69%
|
|
|
Spandidos Publications
3 publications, 0.69%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
2 publications, 0.46%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.46%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 0.46%
|
|
|
American Society for Clinical Investigation
1 publication, 0.23%
|
|
|
IOP Publishing
1 publication, 0.23%
|
|
|
Aging and Disease
1 publication, 0.23%
|
|
|
European Molecular Biology Organization
1 publication, 0.23%
|
|
|
Walter de Gruyter
1 publication, 0.23%
|
|
|
IGI Global
1 publication, 0.23%
|
|
|
S. Karger AG
1 publication, 0.23%
|
|
|
Research Square Platform LLC
1 publication, 0.23%
|
|
|
eLife Sciences Publications
1 publication, 0.23%
|
|
|
Eco-Vector LLC
1 publication, 0.23%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.23%
|
|
|
AMO Publisher
1 publication, 0.23%
|
|
|
OAE Publishing Inc.
1 publication, 0.23%
|
|
|
20
40
60
80
100
120
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.